Fig. 7: %KLRG1 + TIGIT+ of CD8 T cells associated with age and outcome of teplizumab therapy.
From: A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
C-peptide and %KLRG1 + TIGIT+ of CD8 T cells (exhausted T cells) in actively treated individuals (n = 31) from ITN trial of teplizumab. Dashed line and shaded region indicate linear regression line and 95% confidence intervals. a Relationship between increase of exhausted T cells and one-year C-peptide; Pearson correlation (r) of 0.38, p = 0.06. b Relationship between exhausted T cells and QR; r = 0.27, p = 0.20. c Correlation between exhausted T cells and age; r = 0.47, p = 0.007. T cell exhaustion was quantified as the maximum change from baseline at any point during the one year time period after treatment initiation.
